Imeglimin

Drug Profile

Imeglimin

Alternative Names: EMD-387008

Latest Information Update: 13 Jul 2017

Price : $50

At a glance

  • Originator Merck KGaA
  • Developer Poxel
  • Class Amines; Antihyperglycaemics; Small molecules; Triazines
  • Mechanism of Action AMP activated protein kinase stimulants; Glucose modulators; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 30 Jun 2017 Poxel completes a phase II trial in Type 2 diabetes mellitus in Japan (JapicCTI153086)
  • 06 Jun 2017 Updated efficacy and adverse events data from a phase II trial in Type 2 diabetes mellitus released by Poxel
  • 10 May 2017 Poxel plans a phase III program consists of three pivotal trials and non-pivotal studies for Type-2 diabetes mellitus in Japan, in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top